Properties (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:associatedWith |
seizures
psychiatric disorders increased risk of heart attack increased risk of stroke serotonin syndrome |
| gptkbp:clinicalTrials |
cardiovascular safety
long-term use effects weight loss efficacy |
| gptkbp:contraindication |
pregnancy
anorexia bulimia lactation history of cardiovascular disease |
| gptkbp:discontinued |
2010
|
| gptkbp:dosageForm |
capsule
|
| gptkbp:drugInterdiction |
gptkb:MAO_inhibitors
SSRIs other weight loss medications |
| gptkbp:exportMarkets |
2010
|
| gptkbp:formulation |
extended-release
immediate-release |
| https://www.w3.org/2000/01/rdf-schema#label |
Meridia
|
| gptkbp:marketedAs |
gptkb:Abbott_Laboratories
|
| gptkbp:offersCoursesIn |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:New_Zealand gptkb:United_States |
| gptkbp:patentExpiration |
2010
|
| gptkbp:relatedPatent |
obesity
overweight |
| gptkbp:replacedBy |
lifestyle changes
other weight loss medications |
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
insomnia
constipation dry mouth high blood pressure increased heart rate |
| gptkbp:skills |
10 mg
15 mg |
| gptkbp:storage |
room temperature
protected from light protected from moisture |
| gptkbp:symptoms |
anxiety
depression fatigue sleep disturbances irritability |
| gptkbp:triggerType |
serotonin-norepinephrine reuptake inhibitor
|
| gptkbp:type |
sibutramine
|
| gptkbp:usedFor |
weight loss
|